Last reviewed · How we verify
Ovulation triggering with GnRH-a+rhCG
GnRH agonist priming followed by recombinant human chorionic gonadotropin (rhCG) triggers final oocyte maturation and ovulation in assisted reproductive technology cycles.
GnRH agonist priming followed by recombinant human chorionic gonadotropin (rhCG) triggers final oocyte maturation and ovulation in assisted reproductive technology cycles. Used for Ovulation triggering in assisted reproductive technology (ART) cycles, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
At a glance
| Generic name | Ovulation triggering with GnRH-a+rhCG |
|---|---|
| Sponsor | Fundación Santiago Dexeus Font |
| Drug class | Gonadotropin-releasing hormone agonist combined with recombinant human chorionic gonadotropin |
| Target | GnRH receptor (for GnRH-a component); LH/hCG receptor (for rhCG component) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
GnRH agonist (GnRH-a) initially suppresses endogenous LH surge through receptor desensitization, preventing premature ovulation during controlled ovarian hyperstimulation. Subsequent administration of rhCG mimics the natural LH surge, inducing final meiotic maturation of oocytes and triggering ovulation approximately 34–36 hours after injection, enabling precise timing for oocyte retrieval.
Approved indications
- Ovulation triggering in assisted reproductive technology (ART) cycles, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal discomfort or bloating
Key clinical trials
- Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PHASE2)
- Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (NA)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. (PHASE4)
- Dual Trigger for Elective Fertility Preservation (PHASE4)
- Double Stimulation Followed by a Fresh Embryo Transfer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: